Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are uncommon, heterogeneous neoplastic lesions. Angiogenesis, the process of new blood vessel formation, is required for tumour growth, progression and the development of metastases. This process is induced by several growth factors, including vascular endothelial growth factor (VEGF), and transforming growth factor beta 1 (TGF-β1). Endoglin is a co-receptor for TGF-β1 and a marker for angiogenic endothelial cells. The aim of the present study was to evaluate the expression and potential prognostic role of VEGF and endoglin in GEP-NETs.
Introduction
Gastroenteropancreatic neuroendocrine tumours (GEP-NETs), including gastrointestinal carcinoids and pancreatic neuroendocrine tumours (PNETs), comprise a very heterogeneous group of neoplasia, with respect to tumour biology, histocytopathology and prognosis 1 . Despite a slow-growing nature, they are primarily malignant 2 . Angiogenesis, the formation of new blood vessels from the existing vascular bed, is a crucial process in tumour progression. When tumours reach a size of approximately 1 or 2 mm, they become dependent on neovascularisation, not only to provide them with nutrients and oxygen, but also as an exit route for metabolic waste products, further growth of the primary tumour, and eventually, metastatic spread 3 . One of the key factors in angiogenesis is vascular endothelial growth factor (VEGF) which has numerous effects on endothelial cells (ECs), including induction of migration and differentiation 4 .
Several studies have addressed the prognostic implications of VEGF in patients with GEP-NETs, and trials investigating the action of the anti-VEGF antibody bevacizumab in patients with GEP-NETs are ongoing 5, 6 .
Another important growth factor, with a pivotal role in angiogenesis is transforming growth factor beta 1 (TGF-β1), a multifunctional cytokine that is involved in numerous physiological and pathological processes 7 . Endoglin (CD105) is a co-receptor for TGF-β1. As a result of its principal expression on ECs of newly formed blood vessels, several studies have suggested that endoglin is a specific marker of neovascularisation in various cancer types [8] [9] [10] . In pancreatic carcinomas, high endoglin microvessel density (MVD) has been found to be related to shorter survival and therefore, is suggested to be a prognostic marker 11 .
In colorectal cancer, the vessel count by positive endoglin staining is able to identify patients at high risk of metastases 12 .
In the present study, we assessed the tissue expression and levels of two key players in the process of angiogenesis, namely endoglin and VEGF, to assess their potential clinical implications in patients with GEP-NETs.
Materials and Methods

Patients
After surgical removal, tumour tissues were collected at the Department of Gastroenterology, Leiden University Medical Centre (LUMC), Leiden, and either frozen at -80 ○ C and/or embedded in paraffin for immunohistochemical staining.
Sixty-eight homogenates (27 tumour samples and 41 normal samples) of 27 patients were available for the determination of tissue levels of endoglin. For the measurement of VEGF levels, one tumour sample was exhausted; therefore, the total number of tumour samples comprises 26. For CD31 and endoglin immunostaining, 50 and 49 samples, respectively, of 39 patients, were available.
For most patients, but not all, both homogenates and paraffin slides were available. In total, 41 patients with GEP-NETs were included. GEP-NETs comprised pancreatic neuroendocrine tumours (PNETs) and gastrointestinal neuroendocrine tumours, which were also referred to as 'carcinoids'.
Clinicopathological information was obtained by evaluation of patients' medical files and pathology reports, when available. According to the classification of the World Health Organization for GEP-NETs, tumours were categorized into welldifferentiated neuroendocrine tumour (NET), well-differentiated neuroendocrine carcinoma (NEC), or poorly differentiated NEC 13 . From some patients, the WHO classification was not assessable due to the lack of specified classification. This study was performed according to the guidelines of the Medical Ethics Committee of the LUMC in compliance with the Helsinki Declaration.
Immunohistochemistry
Immunohistochemistry was performed as follows. Tissues were fixed in formalin, embedded in paraffin and cut into 5 μm sections. After deparaffinisation and rehydration, endogenous peroxidases were blocked in methanol containing 0.3% H202 (Merck, Darmstadt, Germany). Antigen retrieval was performed by boiling in 0.01M citrate buffer pH 6.0 for 10 minutes. Slides were incubated overnight at room temperature (RT) with primary antibodies: biotinylated goat anti-human endoglin (1:200, R&D Systems Europe, Abingdon, UK), or mouse monoclonal anti-CD31 (1:400, Dako, Glostrup, Denmark) diluted in phosphate-buffered saline (PBS) with 1% bovine serum albumin (BSA), as described previously 14 .
Immunodetection was performed with a biotinylated goat anti-mouse antibody 
Quantitative human endoglin and VEGF determinations in tissue samples
Tissues were homogenized and protein concentrations were determined according to Lowry et al. 14, 15 . Endoglin levels were determined in tissue homogenates, using a commercially available quantitative immunoassay (ELISA) for human endoglin, performed according to the manufacturer's instructions (R&D Systems), as described before 14 . VEGF tissue levels were determined using a commercially available duoset (R&D Systems) as described before 16 . Endoglin and VEGF levels were expressed as ng/mg and pg/mg protein, respectively.
Statistical analysis
Statistical analysis was performed using Statistical Package for Social Sciences version 16 (SPSS) and GraphPad Prism version 5. Unpaired t test and one-way ANOVA were used to compare mean levels of endoglin and VEGF between various data sets. Orthogonal regression analysis and Pearson's correlation (r) were used to explore the relationship between two variables. Survival curves were plotted using the method of Kaplan and Meier. Results are reported as mean ± S.E.
A p-value of <0.05 was considered statistically significant.
Results
Overall, 41 patients with NETs were included (Table 1) Endoglin and VEGF tissue levels were measured in 27 tumour samples from 18 patients with GEP-NETs. Endoglin and VEGF levels were significantly increased in tumours compared to (associated) normal tissues (Table 2) . However, among the various types of GEP-NETs, both endoglin and VEGF levels were comparable.
Interestingly, metastatic tumours showed significantly higher endoglin levels compared to those in primary lesions. VEGF levels were also increased in metastases, although not significantly. Furthermore, well-differentiated NECs showed significantly higher endoglin levels compared to well-differentiated NETs.
Again, this difference in VEGF levels was not statistically significant, although levels in well-differentiated NECs were also increased. Of particular interest, we observed that primary tumour tissues of patients who had developed (lymph node or liver) metastases displayed significantly higher endoglin levels than from those without metastases. Neither endoglin nor VEGF levels were (significantly) related to other clinicopathological parameters including patients' age, sex, the hormonal status (i.e., functional or non-functional) of the PNETs, or the presence of angioinvasion.
Endoglin tissue levels, but not tissue levels of VEGF, were found to increase with tumour size (Figure 1) . Finally, endoglin tumour levels showed no significant correlation with VEGF tumour levels (r=0.11 with P=0.59). The CD31 MVD was found to be significantly higher than the endoglin MVD in 73% of the tumour samples, P<0.01. No significant differences in endoglin and CD31 MVD were observed between carcinoids and PNETs (Table 3) . Furthermore, both endoglin and CD31 MVD were not significantly related to clinicopathological parameters such as patients' age, sex, tumour size, functionality, and angioinvasion. Endoglin tissue levels (ng/mg protein) Microvessel density for endoglin Figure 3 . Correlation analysis of the endoglin MVD and endoglin tissue levels in tumours (n=17). For one patient in whom endoglin tissue levels were assessed, no paraffin slides for MVD determination was available. Endoglin MVD is significantly correlated with tumour levels of endoglin, r=0.64 with p<0.01.
To evaluate the prognostic potential of endoglin and VEGF tissue levels, Kaplan Meier survival analysis was performed (Figure 4 ) by dividing the patients into two groups (i.e. low versus high) using the mean value of endoglin and VEGF tumour levels ( Table 2) . Both endoglin and VEGF tissue levels were not significantly related to patient survival. Furthermore, patients were divided into two groups based on the MVD of endoglin and CD31. Both parameters were not significantly correlated with overall survival of these patients. 
Discussion
In this study, we observed that the expression of the angiogenic cell marker endoglin was related to tumour size, aggressiveness and metastatic potential in patients with GEP-NETs, whereas expression of another key player in angiogenesis, namely VEGF, was not.
In general, GEP-NETs are highly vascularised. In recent years it has become clear that angiogenesis has important effects on tumour progression in several cancers, and the therapeutic role of angiogenesis inhibitors in the treatment of cancers is increasing 17, 18 . In this study, we investigated whether endoglin and VEGF were related to any clinicopathological characteristics of GEP-NETs and evaluated their potential prognostic implications.
By immunohistochemistry, we observed high endoglin expression on vascular ECs in tumour tissues of GEP-NETs. In contrast to CD31, immunopositivity of endoglin was mainly observed on newly formed blood vessels, which indicates that endoglin is more representative of tumour neovascularisation than the panendothelial marker CD31.
Furthermore, we found that endoglin tissue levels were significantly higher in tumours compared to normal tissues. Interestingly, we observed that an increased endoglin expression was indicative of metastatic disease. Endoglin levels were higher in metastases compared to primary tumours, and primary tumours with metastases showed higher endoglin levels compared to tumours without metastases. Additionally, endoglin levels were increased in well-differentiated NECs compared to well-differentiated NETs, and higher endoglin levels were related to larger tumour size in patients with GEP-NETs. In several cancers, the extent of tumour angiogenesis was shown to be reflective of their potency to become invasive and form metastases 19, 20 . Our data indicate that tissue endoglin may serve as a potential assessment marker for the tumour aggressiveness (i.e., NEC versus NET) and the presence of metastases following tumour resection. In the context of anti-cancer therapy, anti-endoglin treatment might provide a new effective anti-angiogenic strategy for GEP-NETs, but more research is needed.
However, several promising in vivo and in vitro studies using anti-endoglin antibodies for anti-cancer treatment have recently been published 21 .
In the present study, we did not evaluate the immunohistochemical expression of revealed that strong expression of VEGF was associated with increased angiogenesis and poor prognosis in patients with GEP-NETs 22, 23 . However, we determined tissue VEGF expression in GEP-NETs and found that VEGF tissue levels showed a similar pattern to endoglin, but were not significantly related to any clinicopathological parameter. Therefore, we assume that, although VEGF is most likely to be involved in the process of neoplastic blood vessel formation in GEP-NETs, this key mediator of angiogenesis is not the appropriate prognostic marker in these tumours. In contrast, our data suggest that endoglin can function as a predictive marker for the development of metastases in GEP-NETs. Endoglin is a co-receptor for TGF-β1. Among the various members of the TGF-β family, TGF-β1 is mostly involved in cancer, and has been shown to stimulate angiogenesis 24 . Endoglin is an important modulator of the TGF-β response, particularly in tumour pathogenesis 25 . In another study by our group, strongly increased tissue levels of endoglin were observed in colorectal cancers, whereas premalignant lesions displayed endoglin levels comparable to those in normal tissues, which supports the pivotal role of endoglin in tumour progression 14 .
The fact that neither endoglin nor VEGF levels were associated with patient survival might be due to the relatively good prognosis of the patients.
Gastrointestinal carcinoids show a 5-year survival rate of about 70%, whereas PNETs have a reported 5-year survival rate ranging from 25 to 100%, even in the case of (unresectable) liver metastases 26, 27 . In our study cohort, 10/18 patients in whom endoglin or VEGF levels were determined were still alive at the end of the study (median survival 8 years), which makes it unlikely to use one of these parameters as a predictor of outcome or survival marker. However, our data support a role for endoglin in identifying patients with GEP-NETs at risk for metastasis.
It is worth reiterating that the current study involved a relatively small number of patients. Nevertheless, GEP-NETs are a rare disease with a low incidence, which leads to general scarcity of patients and samples. However, we believe that the significant differences observed here are representative and illustrate the differential expression pattern of endoglin and VEGF among GEP-NETs.
